Valsts: Izraēla
Valoda: ivrits
Klimata pārmaiņas: Ministry of Health
PRAVASTATIN SODIUM
TEVA ISRAEL LTD
C10AA
טבליה
PRAVASTATIN SODIUM 40 MG
פומי
מרשם נדרש
TEVA ISRAEL LTD, ISRAEL
HMG COA REDUCTASE INHIBITORS
Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Myocardial infa
2022-01-31
Pravastatin Teva MW 07/2023 Notification ( ) " – 1986 20 " : 20 " Pravastatin sodium 20 mg 40 " : 40 " Pravastatin sodium 40 mg 2 " " 6 - ." " . . . , . . . 18 . 1 . ? • . • . • - , . : • "" "" . , , . ) ( . . ,) ( , ,) ( , . ,) ( . . • , ) ( . . , , , , . : Pravastatin Teva MW 07/2023 Notification ( HMG-CoA .) ) ( . 2 . : • )( ( 6 - " " ) . • . • ( " " .) , : • , ( ) ,) ( ( 4 – " .)" • . • 70 . • . • - .) ( • . • ( HMG-CoA ) ( ) . • – . • ( ) . • - 7 ( ) . ( ) . , . . . . . , : • . , . , , . , . . , , , . : • , ( ) Pravastatin Teva MW 07/2023 Notification ( ( B3 ) ) - . • ( , ) , . , 3 " ? " . • , ( ) . , . . , .) ( 4 " " . • " K " , K K . : • ( [ ] ) • ( ) • ( ) • ( ) . , , . , . : • ,) ( . • , , , ( , ) . . • , . , . . . • . , . • - 23 " . Pravastatin Teva MW 07/2023 Notification 3 . ? . . , . . : • : 10-40 . , , " • : 40 , ," . • . . , , . . . . / / 20 :" . 10 ," 10 " . 40 :" . : , , , , , . . • ( ) , , . . , . , . . . , . ! . . . , 4 . , . . . Pravastatin Teva MW 07/2023 Notification : • , , , . , . . • / . : • , , , . • , ) ( , , . : . : ( 1 100 :) • • • • • • • • • • • • • • • • • • ) ( • , ( ) • • ( 1 10,000 :) • , , .) ( • ( lupus erythematous-like syndrome .) • , ( ) • ) ( . • . • ( ) , . . Pravastatin Teva MW 07/2023 Notification ( ) : • . , • : ( 5.6 / , BMI < 30 /" 2 , .) , • .) ( • . • , ( .) • .) ( , , . ( :) • • • • / . • : , . . , , . " ( " www.health.gov.il ) , - : https://sideeffects.health.gov.il 5 . ? • ! / . . • (exp. date) . . • , - 25°C . . • . . . 6 . : , Lactose monohydrate, crospovidone, magnesium stearate. : 20 : " - . , 30 ( ) . 40 : " - , , " P ." 30 ( ) . Pravastatin Teva MW 07/2023 Notification : " , ' 124 , . 2023 . : 20 " 124.64.30379 40 " 124.65.30380 . , . , Izlasiet visu dokumentu